Anne Fassl

Goethe University Frankfurt — Germany

Medicine · Health Sciences

25h-index2.5kcitations81works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(23), Cancer-related Molecular Pathways(13), Advanced Glycation End Products research(9), Advanced Breast Cancer Therapies(8), PARP inhibition in cancer therapy(6)

Publications81 total

Supplementary Table S9 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S3 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Figures from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S5 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S6 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S1 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer
Science Advances·2025· 8 citedOpen Access
Abstract 5715: Enhancing PARP inhibitor efficacy with CDK12/7/9 degradation in prostate cancer
Cancer Research·2025
341 (PB329): Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer
European Journal of Cancer·2024
Impact of homologous recombination repair/BReast CAncer ( <scp> <i>BRCA</i> ) </scp> gene alterations on survival in a real‐world setting of metastatic prostate cancer
British Journal of Urology·2024· 8 citedOpen Access
Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer
2024Open Access
Fluoreszenzbasierte Konfokalmikroskopie – vollständige Digitalisierung der Pathologie
Die Pathologie·2024· 1 citedOpen Access
Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany
European Urology Focus·2024· 6 citedOpen Access
PC4: A new regulator of cyclin D1 transcript levels
The Journal of Cell Biology·2024· 2 citedOpen Access
Heterogeneity and transcriptional drivers of triple-negative breast cancer
Cell Reports·2023· 25 citedOpen Access
Supplementary Table S6 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Piotr Siciński(33), Kornélia Polyák(20), Malvina Papanastasiou(16), Franziska Michor(16), Bojana Jovanović(16), Shawn B. Egri(15), Guillermo Peluffo(15), Jacob D. Jaffe(15), Alexander Meissner(14), Xintao Qiu(14), Anne Trinh(14), Maša Alečković(14), Shaokun Shu(14), Nicholas W. Harper(14), Henry W. Long(14), Laura E. Stevens(13), Daniel Temko(13), Marco Seehawer(13), So Yeon Park(13), Zheqi Li(12)